Screener / SEC EDGAR /CIK 0001581280 /10-K filed Nov 17, 2025, compared with Nov 18, 2024 /Numbers from the XBRL of the 10-Ks
Nasdaq Health care · Biotechnology

Twist Bioscience Corp TWST

Compare with peers Embed
FY2025 at a glance

Sales up 20.3%, free cash flow down to -$75.6M

XBRL, from each 10-K
RevenueStatements
$376.6M from $313.0M in FY2024
FY2017FY2025
Net incomeStatements
-$77.7M from -$208.7M in FY2024
FY2017FY2025
Free cash flowStatements
-$75.6M from -$69.2M in FY2024
FY2017FY2025
EPS (diluted)Statements
$-1.30 from $-3.60 in FY2024
FY2017FY2025
Operating marginStatements
-36.2% from -70.6% in FY2024
FY2017FY2025

The latest figures

Price and key numbers

From EDGAR
All key numbers (36)
EPS (ttm)
-2.23
Sales (ttm)
431.8M
Net income (ttm)
-136.7M
Sales growth
+20.3%
EPS growth
-
Sales Q/Q
+23.2%
Free cash flow
-93.1M
Gross margin
52.0%
Oper. margin
-33.6%
Net margin
-31.7%
FCF margin
-21.6%
R&D / sales
21.3%
Dividend
-
Debt/Eq
-
Curr. ratio
2.67
Cash
117.4M
Op. cash flow (ttm)
-53.1M
EBITDA
-111.4M
EBITDA margin
-29.6%
Quick ratio
2.44
FCF after stock pay
-140.1M
Goodwill / assets
12.8%
Oper. margin low 5y
-115.4%
Stock pay / sales
17.1%
Shares out.
62.7M
Shares Y/Y
+3.1%
Book / share
7.11
Cash / share
1.87
Sales / share
6.89
Asset turnover
0.64
Inventory turns
6.56
Days sales out.
55
Sales 3Y CAGR
+22.8%
Sales 5Y CAGR
+33.1%

Hover or tap a number to see the XBRL line item and filing it comes from; click it to open that filing at SEC. What each number means. Looks wrong? Tell us.

Revenue and net income, FY2017 to FY2025

Each fiscal year from its own 10-K · XBRL

Revenue 376.6M +55.9% a year Net income -77.7M
FY2017 revenue 10.8M · RevenueFromContractWithCustomerIncludingAssessedTax, 0001193125-19-313115 FY2017 net income -59.3M · NetIncomeLoss, 0001193125-19-313115 10.8M FY2017 FY2018 revenue 25.4M · RevenueFromContractWithCustomerIncludingAssessedTax, 0001193125-20-303904 FY2018 net income -71.2M · NetIncomeLoss, 0001193125-20-303904 25.4M FY2018 FY2019 revenue 54.4M · RevenueFromContractWithCustomerIncludingAssessedTax, 0001104659-21-142700 FY2019 net income -107.7M · NetIncomeLoss, 0001104659-21-142700 54.4M FY2019 FY2020 revenue 90.1M · RevenueFromContractWithCustomerIncludingAssessedTax, 0001628280-23-020881 FY2020 net income -139.9M · NetIncomeLoss, 0001628280-23-020881 90.1M FY2020 FY2021 revenue 132.3M · RevenueFromContractWithCustomerIncludingAssessedTax, 0001628280-23-039767 FY2021 net income -152.1M · NetIncomeLoss, 0001628280-23-039767 132.3M FY2021 FY2022 revenue 203.6M · RevenueFromContractWithCustomerIncludingAssessedTax, 0001628280-24-048262 FY2022 net income -217.9M · NetIncomeLoss, 0001628280-24-048262 203.6M FY2022 FY2023 revenue 245.1M · RevenueFromContractWithCustomerIncludingAssessedTax, 0001581280-25-000025 FY2023 net income -204.6M · NetIncomeLoss, 0001581280-25-000025 245.1M FY2023 FY2024 revenue 313.0M · RevenueFromContractWithCustomerIncludingAssessedTax, 0001581280-25-000025 FY2024 net income -208.7M · NetIncomeLoss, 0001581280-25-000025 313.0M FY2024 FY2025 revenue 376.6M · RevenueFromContractWithCustomerIncludingAssessedTax, 0001581280-25-000025 FY2025 net income -77.7M · NetIncomeLoss, 0001581280-25-000025 376.6M FY2025

From XBRL in each 10-K. Hover a bar for the line item and filing. "A year" is the steady yearly growth from FY2017 to FY2025 (8 years).

Growth per share, FY2017 to FY2025

Earnings, book value and free cash flow for each diluted share · 10-K XBRL, every year linked to its filing

Average yearly growth
Book value per share -1.6% a year FY2020 $8.58 to FY2025 $7.91, 5 years
Fiscal year toEPS (diluted)Book value / shareFree cash flow / share
Sep 30, 2025 -$1.30$7.91-$1.26
Sep 30, 2024 -$3.60$8.15-$1.19
Sep 30, 2023 -$3.60$10.96-$2.99
Sep 30, 2022 -$4.04$14.65-$4.20
Sep 30, 2021 -$3.15$12.04-$2.89
Sep 30, 2020 -$3.57$8.58-$3.88
Sep 30, 2019 ---
Sep 30, 2018 ---
Sep 30, 2017 ---

Per share means per diluted weighted-average share of the same fiscal year (the count under diluted EPS, put on today's share count after a split). Book value is shareholders' equity at the year end, including any preferred stock; free cash flow is operating cash flow less capital spending. Each tile's rate is the steady yearly growth from the first to the last year it names: the window starts at the oldest year, up to ten years back, with a value above zero.

What the balance sheet holds, per share

Net current asset value and tangible book value, FY2025 · 10-K XBRL, no share price used

Net current asset value, FY2025, in dollars
  • + Current assets $333.0M
  • − All liabilities $168.9M
  • = Net current asset value $164.1M
Per share, year by year
Tangible book value, FY2025, in dollars
  • + Shareholders' equity $473.0M
  • − Goodwill $82.2M
  • − Other intangible assets $13.4M
  • = Tangible book value $377.3M
Per share, year by year

Net current asset value is current assets minus all liabilities (the long-term ones too), so it is what would be left from the short-term assets after everything owed is paid; it is blank for a bank, which reports no current assets. Tangible book value is shareholders' equity minus goodwill and other intangible assets; equity includes any preferred stock. Both are divided by the diluted weighted-average share count of the same fiscal year. Red bars are amounts taken off, or a negative result.

TWST against Health care peers

Among the 162 companies, the better end on the right. The band holds the middle half; the line is the median.

Ten years, side by side
Sales growth
+4.8%+20.2%
+20.3%38th of 155 · median +10.5%
Net margin
-4.1%15.3%
-31.7%131st of 154 · median 6.8%
Return on equity
-5.2%18.5%
-30.7%124th of 144 · median 9.2%
Free cash flow margin
2.3%19.2%
-21.6%125th of 145 · median 10.0%
TWST and the 5 peers closest in revenue
CompanyRevenue (ttm)Sales growthFYGross marginttmNet marginttmROEttmFCF marginttmDebt / equitylatest
TWST Twist Bioscience Corp$431.8M +20.3%52.0%-31.7%-30.7%-21.6%-
ADMA Adma Biologics, Inc.$519.2M +19.6%68.5%35.1%41.6%25.6%0.45
KRYS Krystal Biotech, Inc.$470.0M +33.9%-47.9%15.7%66.0%-
WGS GeneDx Holdings Corp.$460.8M +40.0%68.7%-24.1%-45.4%-22.0%0.61
ZLAB Zai Lab Ltd$441.7M +15.3%53.4%-44.9%-35.2%-37.0%0.45
PRCT PROCEPT BioRobotics Corp$352.3M +37.2%64.7%-32.6%-34.9%-24.1%0.16
All 162 companies in the group

Where the $376.6M of revenue came from

by product, year to Sep 30, 2025

  • NGS tools $208.1M · 55%
  • Synthetic genes $113.6M · 30%
  • Antibody discovery $23.5M · 6%
  • Oligo pools $20.2M · 5%
  • DNA libraries $11.2M · 3%

From the segment tables in the 10-K XBRL.

Where the return on equity comes from

DuPont: net margin × asset turnover × leverage, FY2025 against FY2020 · 10-K XBRL, year-end balances

Return on equity -16.4% FY2020: -41.6% net income ÷ equity
Net margin -20.6% FY2020: -155.3% profit per $ of sales: -77.7M ÷ 376.6M
Asset turnover 0.59× FY2020: 0.23× sales per $ of assets: 376.6M ÷ 641.9M
Leverage 1.36× FY2020: 1.19× assets per $ of equity: 641.9M ÷ 473.0M

The three parts multiply to the return on equity. A higher return from leverage alone means more debt or less equity (buybacks shrink equity), not a better business. Year-end balances as filed, not averages, so each number is one line of one 10-K; hover a box for its XBRL tags.

Profitability

  • Net margin below the peer median
    -31.7% vs 6.8%
  • Return on equity below 15%
    -30.7%
  • A profit in 0 of 9 years
Net margin, FY2017 to FY2025: -550.8% to -20.6%

Cash and shareholders

  • Free cash flow positive in 0 of 9 years
    −$75.6M last year
  • Share count up over 5 years
    +52.6%
Free cash flow, FY2017 to FY2025: -57.9M to -75.6M

Each tick is a fact with a fixed rule (on /methodology), not a score or advice. A check without the numbers it needs is left out.

Contracted revenue and deferred revenue

Backlog (remaining performance obligations) and cash received in advance, by balance sheet date · XBRL

Remaining performance obligations

Signed, not yet recognized $21.9M revenue under contracts the company has not delivered yet, Jun 30, 2026 · +63.4% on a year earlier

Contract liabilities

Paid in advance $12.1M cash received before delivery, not yet recognized as revenue, Jun 30, 2026 · +94.6% on a year earlier

Both are balance-sheet-date values from the 10-K and 10-Qs. Backlog is what is under contract, not a forecast: contracts can be cancelled or change in size, and a company counts them in its own way. Hover a number for its XBRL line; click it to open the filing.

Income statement, balance sheet and cash flow

Statements · XBRL, each 10-K and 10-Q

From EDGAR

TWST's income statement, balance sheet and cash flow as reported to the SEC in XBRL, one column per fiscal year, the last 9. Hover a number to see the line item and filing it comes from. Where a company changed how it tags a line, the first tag it reported for that period is used. A number looks wrong? Tell us.

Revenue376.6M
FY2017: 10.8MFY2018: 25.4MFY2019: 54.4MFY2020: 90.1MFY2021: 132.3MFY2022: 203.6MFY2023: 245.1MFY2024: 313.0MFY2025: 376.6M FY2017FY2018FY2019FY2020FY2021FY2022FY2023FY2024FY2025
Net income-77.7M
FY2017: -59.3MFY2018: -71.2MFY2019: -107.7MFY2020: -139.9MFY2021: -152.1MFY2022: -217.9MFY2023: -204.6MFY2024: -208.7MFY2025: -77.7M FY2017FY2018FY2019FY2020FY2021FY2022FY2023FY2024FY2025
Free cash flow-75.6M
FY2017: -57.9MFY2018: -69.9MFY2019: -102.7MFY2020: -152.1MFY2021: -139.3MFY2022: -226.2MFY2023: -170.3MFY2024: -69.2MFY2025: -75.6M FY2017FY2018FY2019FY2020FY2021FY2022FY2023FY2024FY2025
Free cash flow after stock pay-140.1M
FY2017: -59.8MFY2018: -72.8MFY2019: -113.9MFY2020: -169.2MFY2021: -176.3MFY2022: -305.9MFY2023: -200.5MFY2024: -120.1MFY2025: -140.1M FY2017FY2018FY2019FY2020FY2021FY2022FY2023FY2024FY2025
EPS (diluted)-1.30
FY2017: -24.49FY2018: -25.51FY2019: -3.92FY2020: -3.57FY2021: -3.15FY2022: -4.04FY2023: -3.60FY2024: -3.60FY2025: -1.30 FY2017FY2018FY2019FY2020FY2021FY2022FY2023FY2024FY2025
Diluted shares59.8M
FY2017: -FY2018: -FY2019: -FY2020: 39.2MFY2021: 48.3MFY2022: 53.9MFY2023: 56.9MFY2024: 58.0MFY2025: 59.8M FY2017FY2018FY2019FY2020FY2021FY2022FY2023FY2024FY2025

Revenue by product or service

year to Sep 30, 2025
RevenueSharevs year before
NGS tools 208.1M55.3% +23.0%
Synthetic genes 113.6M30.2% +22.6%
Antibody discovery 23.5M6.2% +15.4%
Oligo pools 20.2M5.4% +19.7%
DNA libraries 11.2M3.0% -19.7%

10-K 0001581280-25-000025, segment and revenue notes (XBRL).

Revenue by region

year to Sep 30, 2025
RevenueSharevs year before
Americas 225.6M59.9% +16.3%
EMEA 124.2M33.0% +34.2%
APAC 26.8M7.1% +0.9%

10-K 0001581280-25-000025, segment and revenue notes (XBRL).

Income statement

From EDGAR
FY2017FY2018FY2019FY2020FY2021FY2022FY2023FY2024FY2025
Revenue10.8M25.4M54.4M90.1M132.3M203.6M245.1M313.0M376.6M
Cost of revenue24.0M32.2M47.4M61.4M80.6M119.3M155.4M179.6M185.6M
R&D19.2M20.3M35.7M43.0M69.1M120.3M106.9M90.9M80.3M
SG&A26.1M43.5M80.1M103.3M135.9M212.9M189.7M218.4M247.0M
Operating income-58.5M-70.6M-108.8M-140.1M-152.7M-234.8M-217.2M-220.8M-136.3M
Interest expense905K1.3M1.3M787K367K80K5K29K-
Pretax income-59.0M-71.0M-107.4M-139.5M-154.0M-228.3M-203.5M-208.2M-77.0M
Income tax280K242K292K382K-1.9M-10.4M1.2M560K719K
Net income-59.3M-71.2M-107.7M-139.9M-152.1M-217.9M-204.6M-208.7M-77.7M
EPS (diluted)-24.49-25.51-3.92-3.57-3.15-4.04-3.60-3.60-1.30
Diluted shares---39.2M48.3M53.9M56.9M58.0M59.8M
Depreciation & amortization5.0M5.7M6.1M6.7M9.8M16.5M29.3M31.4M24.9M
EBITDA-53.5M-64.8M-102.7M-133.4M-143.0M-218.3M-187.8M-189.4M-111.4M
Operating margin-543.2%-277.5%-200.1%-155.5%-115.4%-115.3%-88.6%-70.6%-36.2%
Net margin-550.8%-280.2%-198.0%-155.3%-114.9%-107.0%-83.5%-66.7%-20.6%
Revenue growth-+136%+114%+65.7%+46.9%+53.8%+20.4%+27.7%+20.3%

Cash flow

From EDGAR
FY2017FY2018FY2019FY2020FY2021FY2022FY2023FY2024FY2025
Operating cash flow-51.3M-66.2M-87.9M-142.3M-112.2M-124.4M-142.5M-64.1M-47.6M
Capital spending6.6M3.7M14.8M9.9M27.1M101.9M27.8M5.1M28.0M
Free cash flow-57.9M-69.9M-102.7M-152.1M-139.3M-226.2M-170.3M-69.2M-75.6M
Stock-based pay (added back)1.9M3.0M11.2M17.1M37.0M79.7M30.3M50.9M64.5M
Free cash flow after stock pay-59.8M-72.8M-113.9M-169.2M-176.3M-305.9M-200.5M-120.1M-140.1M
Acquisitions---0483K8.2M00-
Debt raised2.2M--------
Debt repaid4.2M-2.5M3.3M3.3M1.6M00-
Investing cash flow-10.0M27.3M-104.8M-114.7M156.2M-232.9M50.6M-3.1M-24.8M
Financing cash flow63.8M88.8M158.6M303.7M329.2M270.5M911K6.9M28.5M

Stock-based pay and leases

From EDGAR
FY2017FY2018FY2019FY2020FY2021FY2022FY2023FY2024FY2025
Stock-based pay (expense)1.9M3.0M11.2M17.1M37.0M79.7M30.3M50.9M64.5M
Stock-based pay / revenue17.6%11.6%20.5%19.0%28.0%39.1%12.4%16.3%17.1%
Operating lease cost------16.2M15.6M15.1M
Operating lease cash paid---9.0M8.0M13.0M14.6M14.7M14.9M
Right-of-use assets---33.7M61.6M74.9M71.5M58.8M49.4M
Operating lease liabilities---31.2M61.4M94.9M94.1M85.0M75.6M

From SEC's XBRL company facts (data.sec.gov). EBITDA = operating income + depreciation and amortization; free cash flow = operating cash flow - capital spending; total debt = long-term debt (with its current part) + short-term borrowings. Stock-based pay and leases are shown as the company reports them; Tickdelta does not take them out of earnings or add leases to debt. Click a number to open the filing in SEC's Inline XBRL viewer, where you can click the same number to see how it is tagged. Values a company later revised show as revised; the Revised numbers tab lists the changes.

Sources

Every figure is from the company's XBRL filed with each 10-K and 10-Q (data.sec.gov). Hover a number for its line item; click it to open the filing.

Also

Company numbers: the figures the company reports beyond the statements. Peers: ten years, side by side.

Work with it

Excel workbook · CSV. Google Sheet that stays up to date: paste =IMPORTDATA("https://tickdelta.com/company/TWST/export.csv") into a cell.

Next:Peers in numbers
Esc

Type a ticker such as AAPL, a name, an investor such as Buffett, or a topic such as tariffs. ↑ ↓ to move, Enter to open.